Abstract: The present disclosure provides surprisingly useful fusion polypeptides including an immunomodulatory moiety and a metal-hydroxide binding moiety, as well as various related technologies, including methods of making and of using such fusion polypeptides.

Abstract: Featured herein are pharmaceutical compositions and formulations containing an interleukin-6 (IL-6) antagonist, e.g., an IL-6 antibody molecule, designed for administration for a subject. The pharmaceutical compositions and formulations provided herein are suitable for use in manufacture of medicaments or methods of treating subjects with IL-6 associated diseases, e.g., ocular diseases associated with elevated levels of IL-6.

Abstract: Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6 related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.

Abstract: The present disclosure relates to, inter alia, stable formulations comprising an antibody that binds human CD137 or antigen binding fragments thereof, and to use of the formulations in methods for treating, or ameliorating various diseases and conditions, including cancer, that are amenable to treatment with a CD137 antibody.

Abstract: Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6-related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.

Abstract: Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6-related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.

Abstract: Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6 related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.

Abstract: Featured herein are pharmaceutical compositions and formulations containing an interleukin-6 (IL-6) antagonist, e.g., an IL-6 antibody molecule, designed for administration for a subject. The pharmaceutical compositions and formulations provided herein are suitable for use in manufacture of medicaments or methods of treating subjects with IL-6 associated diseases, e.g., ocular diseases associated with elevated levels of IL-6.

Abstract: The present invention relates to a method for clarification of, and removal of host cell proteins from, a cell broth consisting essentially of viable cells, a culture medium and a secreted desired biological substance having an overall positive charge in the cell broth by contacting the cell broth with a particulate anion exchanger, allowing an adequate incubation time to result in formation of a cell pellet and a supernatant layer, separating the resulting cell pellet from the supernatant layer. The present invention further relates to a method for the recovery of a secreted desired biological substance from the cell broth by extracting the secreted desired biological substance from the supernatant layer.